Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2019

01-10-2019 | Crohn's Disease | Original Article

Association Between Cannabis Use and Complications Related to Crohn’s Disease: A Retrospective Cohort Study

Authors: Chimezie Mbachi, Bashar Attar, Yuchen Wang, Isaac Paintsil, Benjamin Mba, Setri Fugar, Rohit Agrawal, Roberto Carlos Simons-Linares, Palash Jaiswal, William Trick, Vikram Kotwal

Published in: Digestive Diseases and Sciences | Issue 10/2019

Login to get access

Abstract

Background

Crohn’s disease is an idiopathic inflammatory process that is occasionally associated with complications, which cause significant morbidity and mortality. The anti-inflammatory effect of cannabis in intestinal inflammation has been shown in several experimental models; it is unknown whether this correlates with fewer complications in Crohn’s disease patients.

Aims

To compare the prevalence of Crohn’s disease-related complications among cannabis users and non-users in patients admitted with a primary diagnosis of Crohn’s disease or a primary diagnosis of Crohn’s related complication and a secondary diagnosis of Crohn’s disease between 2012 and 2014.

Methods

We used data from the Healthcare Cost and Utilization Project–National Inpatient Sample. Cannabis users (615) were compared directly after propensity score match to non-users, in aspects of various complications and clinical end-points.

Results

Among matched cohorts, Cannabis users were less likely to have the following: active fistulizing disease and intra-abdominal abscess (11.5% vs. 15.9%; aOR 0.68 [0.49 to 0.94], p = 0.025), blood product transfusion (5.0% vs. 8.0%; aOR 0.48 [0.30 to 0.79], p = 0.037), colectomy (3.7% vs. 7.5%; aOR 0.48 [0.29–0.80], p = 0.004), and parenteral nutrition requirement (3.4% vs. 6.7%, aOR 0.39 [0.23 to 0.68], p = 0.009).

Conclusion

Cannabis use may mitigate several of the well-described complications of Crohn’s disease among hospital inpatients. These effects could possibly be through the effect of cannabis in the endocannabinoid system.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.CrossRefPubMed Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.CrossRefPubMed
2.
go back to reference Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology. 2007;133:1327–1339.CrossRefPubMed Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology. 2007;133:1327–1339.CrossRefPubMed
3.
go back to reference Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955.CrossRefPubMedPubMedCentral Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955.CrossRefPubMedPubMedCentral
5.
go back to reference Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.CrossRefPubMed Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.CrossRefPubMed
6.
go back to reference Kilmer B. Recreational cannabis—minimizing the health risks from legalization. N Engl J Med. 2017;376:705–707.CrossRefPubMed Kilmer B. Recreational cannabis—minimizing the health risks from legalization. N Engl J Med. 2017;376:705–707.CrossRefPubMed
7.
go back to reference Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–1685.CrossRefPubMed Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–1685.CrossRefPubMed
8.
go back to reference Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006;291:G364–G371.CrossRefPubMed Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006;291:G364–G371.CrossRefPubMed
9.
go back to reference Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol. 2012;258:256–267.CrossRefPubMed Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol. 2012;258:256–267.CrossRefPubMed
10.
go back to reference Montecucco F, Lenglet S, Braunersreuther V, et al. CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol. 2009;46:612–620.CrossRefPubMed Montecucco F, Lenglet S, Braunersreuther V, et al. CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol. 2009;46:612–620.CrossRefPubMed
11.
go back to reference Mohnle P, Schutz SV, Schmidt M, et al. MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. Biochem Biophys Res Commun. 2014;451:516–521.CrossRefPubMed Mohnle P, Schutz SV, Schmidt M, et al. MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. Biochem Biophys Res Commun. 2014;451:516–521.CrossRefPubMed
12.
go back to reference Duerr GD, Heinemann JC, Dunkel S, et al. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci. 2013;92:976–983.CrossRefPubMed Duerr GD, Heinemann JC, Dunkel S, et al. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci. 2013;92:976–983.CrossRefPubMed
13.
go back to reference Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology. 2011;53:346–355.CrossRefPubMed Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology. 2011;53:346–355.CrossRefPubMed
14.
go back to reference Jenkin KA, Verty AN, McAinch AJ, Hryciw DH. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. Int J Biochem Cell Biol. 2012;44:2028–2031.CrossRefPubMed Jenkin KA, Verty AN, McAinch AJ, Hryciw DH. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. Int J Biochem Cell Biol. 2012;44:2028–2031.CrossRefPubMed
15.
go back to reference Adegbala O, Martin KD, Otuada D, Akinyemiju T. Diabetes mellitus with chronic complications in relation to carotid endarterectomy and carotid artery stenting outcomes. J Stroke Cerebrovasc Dis. 2017;26:217–224.CrossRefPubMed Adegbala O, Martin KD, Otuada D, Akinyemiju T. Diabetes mellitus with chronic complications in relation to carotid endarterectomy and carotid artery stenting outcomes. J Stroke Cerebrovasc Dis. 2017;26:217–224.CrossRefPubMed
16.
go back to reference Micic D, Gaetano JN, Rubin JN, et al. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS ONE. 2017;12:e0182900.CrossRefPubMedPubMedCentral Micic D, Gaetano JN, Rubin JN, et al. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS ONE. 2017;12:e0182900.CrossRefPubMedPubMedCentral
17.
go back to reference Rumalla K, Reddy AY, Mittal MK. Association of recreational marijuana use with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2016;25:452–460.CrossRefPubMed Rumalla K, Reddy AY, Mittal MK. Association of recreational marijuana use with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2016;25:452–460.CrossRefPubMed
18.
go back to reference Adejumo AC, Alliu S, Ajayi TO, et al. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: a cross-sectional study. PLoS ONE. 2017;12:e0176416.CrossRefPubMedPubMedCentral Adejumo AC, Alliu S, Ajayi TO, et al. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: a cross-sectional study. PLoS ONE. 2017;12:e0176416.CrossRefPubMedPubMedCentral
19.
go back to reference Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed
20.
go back to reference Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.CrossRef Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.CrossRef
21.
go back to reference Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.CrossRefPubMed Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.CrossRefPubMed
22.
go back to reference Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.CrossRefPubMed Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.CrossRefPubMed
23.
go back to reference Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMed Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMed
24.
go back to reference Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.PubMed Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.PubMed
25.
go back to reference Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280e1271.CrossRefPubMed Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280e1271.CrossRefPubMed
Metadata
Title
Association Between Cannabis Use and Complications Related to Crohn’s Disease: A Retrospective Cohort Study
Authors
Chimezie Mbachi
Bashar Attar
Yuchen Wang
Isaac Paintsil
Benjamin Mba
Setri Fugar
Rohit Agrawal
Roberto Carlos Simons-Linares
Palash Jaiswal
William Trick
Vikram Kotwal
Publication date
01-10-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05556-z

Other articles of this Issue 10/2019

Digestive Diseases and Sciences 10/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.